Cambrian Bio Reports Positive Phase 1b ATX-304 Data
NEW YORK, N.Y. | June 18, 2026 Cambrian Bio has presented positive Phase 1b clinical data for ATX-304, the...
ADA 2026
Advertisement
Caliway Presents CBL-514 Data Showing Reduced Weight Regain with GLP-1 Therapies
June 10, 2026 – Taipei, Taiwan Caliway Biopharmaceuticals announced new preclinical data demonstrating the potential of its proprietary fat-reduction...
insitro Advances AI-Discovered CTRO-1013 for MASH With Anti-Fibrotic Data
NEW ORLEANS, June 8, 2026 insitro announced new preclinical findings from its lead metabolic dysfunction-associated steatohepatitis (MASH) program, demonstrating...
IBA Receives FDA Approval for First ConformalFLASH Human Trial
LOUVAIN-LA-NEUVE, Belgium – June 9, 2026 IBA (Ion Beam Applications), the global leader in proton therapy technology, has achieved...
Engitix and GSK Partner to Advance Liver Fibrosis Drug Discovery
London, UK – June 8, 2026 Engitix Ltd., a biotechnology company specializing in extracellular matrix (ECM)-driven drug discovery, has...
Advertisements
Lilly’s Foundayo Outperforms Rivals in Landmark Diabetes Trials
INDIANAPOLIS, USA – June 8, 2026 Eli Lilly and Company has reported compelling new Phase 3 clinical data showing...
Ascletis Showcases ASC30, ASC37 and ASC39 Obesity Data at ADA 2026
HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...
Boehringer’s Survodutide Delivers Major Metabolic Benefits
INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...
Antag Therapeutics Reports Positive Phase 1 Results for AT7687 in Obesity
COPENHAGEN, Denmark, June 7, 2026 Antag Therapeutics presented positive Phase 1 clinical results and new preclinical findings for AT7687,...
Novo Nordisk’s CagriSema Delivers Strong HbA1c and Weight Loss Results in Phase 3 REIMAGINE Trials
Plainsboro, New Jersey and Bagsværd, Denmark, June 7, 2026 Novo Nordisk has unveiled compelling Phase 3 clinical data for...
Advertisement
